1. Home
  2. BOLD vs CLPS Comparison

BOLD vs CLPS Comparison

Compare BOLD & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • CLPS
  • Stock Information
  • Founded
  • BOLD 2018
  • CLPS 2005
  • Country
  • BOLD United States
  • CLPS Hong Kong
  • Employees
  • BOLD N/A
  • CLPS N/A
  • Industry
  • BOLD
  • CLPS Computer Software: Prepackaged Software
  • Sector
  • BOLD
  • CLPS Technology
  • Exchange
  • BOLD Nasdaq
  • CLPS Nasdaq
  • Market Cap
  • BOLD 33.4M
  • CLPS 26.8M
  • IPO Year
  • BOLD 2024
  • CLPS 2018
  • Fundamental
  • Price
  • BOLD $1.25
  • CLPS $0.87
  • Analyst Decision
  • BOLD Buy
  • CLPS
  • Analyst Count
  • BOLD 4
  • CLPS 0
  • Target Price
  • BOLD $4.00
  • CLPS N/A
  • AVG Volume (30 Days)
  • BOLD 143.3K
  • CLPS 313.1K
  • Earning Date
  • BOLD 11-05-2025
  • CLPS 10-17-2025
  • Dividend Yield
  • BOLD N/A
  • CLPS 14.95%
  • EPS Growth
  • BOLD N/A
  • CLPS N/A
  • EPS
  • BOLD N/A
  • CLPS N/A
  • Revenue
  • BOLD N/A
  • CLPS $164,481,414.00
  • Revenue This Year
  • BOLD N/A
  • CLPS N/A
  • Revenue Next Year
  • BOLD N/A
  • CLPS N/A
  • P/E Ratio
  • BOLD N/A
  • CLPS N/A
  • Revenue Growth
  • BOLD N/A
  • CLPS 15.17
  • 52 Week Low
  • BOLD $1.00
  • CLPS $0.80
  • 52 Week High
  • BOLD $3.75
  • CLPS $1.88
  • Technical
  • Relative Strength Index (RSI)
  • BOLD 40.98
  • CLPS 42.84
  • Support Level
  • BOLD $1.37
  • CLPS $0.84
  • Resistance Level
  • BOLD $1.52
  • CLPS $0.90
  • Average True Range (ATR)
  • BOLD 0.07
  • CLPS 0.08
  • MACD
  • BOLD -0.03
  • CLPS -0.01
  • Stochastic Oscillator
  • BOLD 6.25
  • CLPS 12.32

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

Share on Social Networks: